The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: Initial results of endocrinological and biochemical efficacies in patients with prostate cancer

Journal of Urology

Volumn 165, Issue 5 I, 2001, Pages 1585-1589

  Tomera, Kevin ^b   Gleason, Donald ^b   Gittelman, Marc ^b   Moseley, William ^b   Zinner, Norman ^b   Murdoch, Myron ^b   Menon, Mani ^b   Campion, Marilyn ^b   Garnick, Marc B ^b  

^a Alaska Clinical Research Center   (United States)

^b NONE

Author keywords

Androgen antagonists; Gonadorelin; Hormones; Prostatic neoplasms; Therapeutics

Indexed keywords

ABARELIX; GONADORELIN ANTAGONIST; GOSERELIN; LEUPRORELIN;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CASTRATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HORMONAL REGULATION; HORMONE RESPONSE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; STEROIDOGENESIS; TESTOSTERONE RELEASE;

EID: 0035046991     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-5347(05)66353-7     Document Type: Article

References (9)

1. Studies on prostate cancer. I. The effect of castration, estrogen and of androgen injections on serum phosphatase in metastatic carcinoma of the prostate
2. Leuprolide versus diethylstilbesterol for metastatic prostate cancer
3. Prevention of the transient adverse effects of gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of antiandrogen (nilutamide)
4. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate
5. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate
6. Suppression of plasma gonadotropins by abarelix: A potent new LHRH antagonist
7. Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hyperplasia
8. Antiandrogens: A summary review of pharmacodynamic properties and tolerability in prostate cancer therapy
9. Tailoring of hormonal therapy in prostate cancer